LONDON (Reuters) - Philip Morris International (NYSE:PM) (PMI) on Thursday signalled a slower than anticipated U.S. roll out of its IQOS heated tobacco device, a choice analysts said was positive for its competitors in the short term.
The New York-listed Marlboro maker also said it aims for more than two thirds of its net revenues to come from "smoke-free" products by 2030, up from 50% in 2025, as it tries to transform its image from a cigarette purveyor to a driver of the shift to healthier alternatives.
Investors have been closely watching IQOS' entry into the U.S., the world's largest market for nicotine products, and had been expecting it from May 2024 next year. Reuters reported on Wednesday that PMI is hiring lobbyists across a host of key U.S. states ahead of the launch.
Chief Executive Jacek Olczak said IQOS would launch in four cities in two unnamed U.S. states from 2024, but a national launch would only come after PMI receives approval to sell the latest version, known as IQOS ILUMA.
The company was planning to apply for approval in October and expected it from 2025, he continued.
"We need to warm up the tyres," he said of the initial launch, which would help PMI fine tune its approach.
A national roll-out of ILUMA would follow but in phases, he continued, adding launching in 10 states in the first year would make sense.
Meaningful traction for PMI's heated tobacco products in the U.S. "now looks delayed until ILUMA," Owen Bennett, equity analyst at Jefferies, said in a note, adding this was a positive for PMI's rivals.
Olczak also signalled that PMI's push into non-nicotine products was no longer a priority. It recently scrapped an ambition for $1 billion in net revenues to come from sales of such products by 2025.
Instead, PMI will focus its resources on IQOS and nicotine pouch brand ZYN, Olczak said, adding it had been too optimistic around acceptance of big tobacco companies operating outside of nicotine.
PMI also announced updated medium-term targets including for revenue and earnings per share, and ambitious volume targets for IQOS and ZYN.
ZYN and other oral nicotine products in the U.S. would help drive an expected $2 billion in revenues there in 2024, even before IQOS ILUMA, executives said.
PMI shares were up 1.5% on Thursday.